trending Market Intelligence /marketintelligence/en/news-insights/trending/ZZZaYj15_-6GLTJCB6A_mw2 content esgSubNav
In This List

Former Regulus Therapeutics exec joins AmpliPhi Biosciences as CEO

Blog

Commercial Banking: June 22nd Edition

Blog

Understanding Loss Given Default A Review of Three Approaches

Blog

Commercial Banking Newsletter June Edition - 2022

Blog

Insight Weekly: US recession outlook; mortgage activity slowdown; climate disclosure push


Former Regulus Therapeutics exec joins AmpliPhi Biosciences as CEO

AmpliPhi Biosciences Corp. appointed Paul Grint to the position of CEO, effective May 31.

Grint previously worked as president and CEO of biopharmaceutical company Regulus Therapeutics Inc.

M. Scott Salka has resigned as CEO and director of AmpliPhi and will serve as a consultant to the company during a transition period.